<p>2025 年 11 月 17 日- 上午 01:52</p>
<p>纽约，2025 年 11 月 17 日（GLOBE NEWSWIRE）-- Mesoblast Limited（纳斯达克：MESO；澳大利亚证券交易所：MSB），全球领先的用于治疗炎症疾病的同种异体细胞药物的公司，今天宣布，随着公司向完全整合的商业组织过渡，已任命 James M. O’Brien 为其美国首席财务官（CFO）。Jim 在财务管理和规划的各个方面拥有丰富的经验，职业生涯的大部分时间都在生命科学、生物技术和制药行业的跨国公共和私人公司工作。</p>
<p>Mesoblast 首席执行官 Dr Silviu Itescu 表示：“我们非常高兴 Jim 能加入 Mesoblast。他在跨职能财务方面的深厚专业知识和对美国市场的了解，填补了我们向成熟商业组织过渡过程中的关键高级领导职位。Jim 的丰富经验将为 Mesoblast 提供所需的财务领导，以便在商业化 Ryoncil®并期待标签扩展时发挥作用。他的技能将与我们的财务负责人 Andrew Chaponnel 的技能相辅相成，实施与收入预测、融资和资本分配相关的稳健财务控制、报告和治理。”</p>
<p>Jim 在 Actavis plc 担任全球责任，监督公司和业务单位的财务、报告、内部控制和会计运营，该公司随后收购了 Allergan plc，之后又被 AbbVie Inc.收购。Jim 创建了一个世界级的财务预算和预测流程，以跟踪业务绩效和趋势，并开发了支持一系列公司活动的财务工具和分析，包括商业战略和公司发展，整合国际业务收购并管理近 100 亿美元交易的活动。在他的任期内，Actavis 的预估收入超过 80 亿美元。此前，Jim 在 Nycomed 建立了一个财务团队，负责监督所有供应链和收入管理，该公司是一家私募股权拥有的公司，年收入为 7.5 亿美元，后来以 15 亿美元被 Sandoz 收购。Jim 最近的 CFO 角色包括纳斯达克上市的生物制药公司 Cognition Therapeutics, Inc.，监督公司的成功首次公开募股，以及在双重上市的芬兰生物技术公司 Faron Pharmaceuticals, Ltd.的工作。他还曾在百时美施贵宝（Bristol-Myers Squibb，BMS）担任财务职务。Jim 是一名注册会计师，曾在纽约和华盛顿特区的普华永道工作。</p>
<p><strong>关于 Mesoblast</strong></p>
<p>Mesoblast（公司）是开发用于治疗严重和危及生命的炎症疾病的同种异体（现成）细胞药物的全球领导者。该公司的专有间充质谱系细胞治疗技术平台的疗法通过释放抗炎因子来应对严重炎症，这些因子对免疫系统的多个效应臂进行反制和调节，从而显著减少有害的炎症过程。</p>
<p>Mesoblast 的 Ryoncil®（remestemcel-L-rknd）用于治疗 2 个月及以上儿童患者的类固醇难治性急性移植物抗宿主病（SR-aGvHD），是首个获得 FDA 批准的间充质基质细胞（MSC）疗法。请参见 www.ryoncil.com 上的完整处方信息。</p>
<p>Mesoblast 致力于基于其 remestemcel-L 和 rexlemestrocel-L 同种异体基质细胞技术平台开发针对不同适应症的额外细胞疗法。Ryoncil®正在开发用于包括成人 SR-aGvHD 和生物制剂耐药性炎症性肠病在内的其他炎症疾病。Rexlemestrocel-L 正在开发用于心力衰竭和慢性下背痛。该公司已在日本、欧洲和中国建立了商业合作伙伴关系。</p>
<p><strong>关于 Mesoblast 的知识产权：</strong> Mesoblast 拥有强大而广泛的全球知识产权组合，拥有超过 1000 项已授予的专利或专利申请，涵盖间充质基质细胞的物质组成、制造方法和适应症。这些已授予的专利和专利申请提供了商业保护，延续至至少 2044 年，涵盖所有主要市场。</p>
<p><strong>关于 Mesoblast 的制造：</strong> 该公司的专有制造工艺可生产工业规模的、冷冻保存的、现成的细胞药物。这些细胞疗法具有明确的药品释放标准，计划在全球范围内为患者提供。</p>
<p>Mesoblast 在澳大利亚、美国和新加坡设有办事处，并在澳大利亚证券交易所（MSB）和纳斯达克（MESO）上市。有关更多信息，请访问 www.mesoblast.com，LinkedIn: Mesoblast Limited 和 Twitter: @Mesoblast</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含与未来事件或我们未来财务表现相关的前瞻性声明，并涉及已知和未知的风险、不确定性及其他因素，这些因素可能导致我们的实际结果、活动水平、表现或成就与这些前瞻性声明所表达或暗示的任何未来结果、活动水平、表现或成就存在重大差异。我们根据 1995 年《私人证券诉讼改革法案》和其他联邦证券法的安全港条款作出此类前瞻性声明。前瞻性声明不应被视为对未来表现或结果的保证，实际结果可能与这些前瞻性声明中预期的结果不同，而这些差异可能是重大且不利的。前瞻性声明包括但不限于关于：Mesoblast 的临床前和临床研究的启动、时间、进展和结果，以及 Mesoblast 的研发项目；Mesoblast 将产品候选者推进、招募并成功完成临床研究（包括多国临床试验）的能力；Mesoblast 提升其制造能力的能力；监管申请和批准、制造活动和产品营销活动的时间或可能性（如有）；Mesoblast 的 RYONCIL 用于儿童 SR-aGVHD 的商业化及任何其他产品候选者（如获批准）；围绕干细胞治疗的监管或公众认知及市场接受度；Mesoblast 的产品候选者（如有获批准）因患者不良事件或死亡而可能被撤回市场的潜在性；战略合作协议的潜在利益及 Mesoblast 进入和维持已建立的战略合作的能力；Mesoblast 在其产品候选者上建立和维持知识产权的能力，以及在涉嫌侵权案件中成功捍卫这些权利的能力；Mesoblast 能够为其产品候选者和技术建立和维持的知识产权保护范围；Mesoblast 的费用、未来收入、资本需求及其对额外融资的需求的估计；Mesoblast 的财务表现；与 Mesoblast 的竞争对手和行业相关的发展；以及 Mesoblast 的产品候选者（如获批准）的定价和报销。您应将本新闻稿与我们最近提交给 SEC 的报告或我们网站上的风险因素一起阅读。可能导致 Mesoblast 的实际结果、表现或成就与此类声明所表达或暗示的结果存在重大差异的不确定性和风险，因此，您不应对这些前瞻性声明过度依赖。我们不承担任何公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来发展还是其他原因。</p>
<p>发布经首席执行官授权。</p>
<p><em>如需更多信息，请联系：</em></p>
<p><em><strong>企业传播 / 投资者</strong></em></p>
<p>保罗·休斯</p>
<p>电话：+61 3 9639 6036</p>
<p><em><strong>媒体</strong></em> <em><strong>– 全球</strong></em></p>
<p>艾莉森全球</p>
<p>艾玛·尼尔</p>
<p>电话：+1 603 545 4843</p>
<p>电子邮件：emma.neal@allisonworldwide.com</p>
<p><em><strong>媒体 – 澳大利亚</strong></em></p>
<p>蓝点媒体</p>
<p>史蒂夫·达布科夫斯基</p>
<p>电话：+61 419 880 486</p>
<p>电子邮件：steve@bluedot.net.au</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVM05qZzFOQ00zTWpZMk9UVXpJekl3TVRjME16ST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVM05qZzFOQ00zTWpZMk9UVXpJekl3TVRjME16ST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmEyNTdkZTEtYjA1OS00NGRhLWFjZDQtMjI1ZmVkYjU4YTQwLTEwMjkwMDUtMjAyNS0xMS0xNy1lbg==/tiny/Mesoblast-Limited.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmEyNTdkZTEtYjA1OS00NGRhLWFjZDQtMjI1ZmVkYjU4YTQwLTEwMjkwMDUtMjAyNS0xMS0xNy1lbg==/tiny/Mesoblast-Limited.png"/></p>

MESO

<p>Mesoblast Limited 任命 James M. O’Brien 为其美国首席财务官。O’Brien 在 Actavis、Nycomed、Cognition Therapeutics 和 Faron Pharmaceuticals 的职位上积累了丰富的财务管理经验。他的任命是 Mesoblast 向全面整合的商业组织过渡的一部分，专注于商业化 Ryoncil® 并扩展其适应症。Mesoblast 是治疗炎症性疾病的异体细胞药物的领导者，拥有强大的全球知识产权组合和制造能力</p>

<p>11/17/2025 - 01:52 AM</p>
<div class="lb-trans"><p>2025 年 11 月 17 日- 上午 01:52</p>
</div><p>NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company’s transition to a fully integrated commercial organization it has appointed James M. O’Brien as its US-based Chief Financial Officer (CFO). Jim has extensive experience in all aspects of financial management and planning having spent the majority of his career with multi-national public and private companies in the life sciences, biotechnology, and pharmaceutical industries.</p>
<div class="lb-trans"><p>纽约，2025 年 11 月 17 日（GLOBE NEWSWIRE）-- Mesoblast Limited（纳斯达克：MESO；澳大利亚证券交易所：MSB），全球领先的用于治疗炎症疾病的同种异体细胞药物的公司，今天宣布，随着公司向完全整合的商业组织过渡，已任命 James M. O’Brien 为其美国首席财务官（CFO）。Jim 在财务管理和规划的各个方面拥有丰富的经验，职业生涯的大部分时间都在生命科学、生物技术和制药行业的跨国公共和私人公司工作。</p>
</div><p>Mesoblast CEO Dr Silviu Itescu said: “We are very pleased to have Jim join us at Mesoblast. His deep cross functional financial expertise and knowledge of US markets fills a key senior leadership position as we transition to a mature commercial organization. Jim’s extensive experience will provide Mesoblast with the financial leadership required as it commercializes Ryoncil® and looks forward to label expansion. His skillsets will complement those of Andrew Chaponnel, our Head of Finance, implementing robust financial controls, reporting and governance related to revenue forecasting, financing, and capital allocation.”</p>
<div class="lb-trans"><p>Mesoblast 首席执行官 Dr Silviu Itescu 表示：“我们非常高兴 Jim 能加入 Mesoblast。他在跨职能财务方面的深厚专业知识和对美国市场的了解，填补了我们向成熟商业组织过渡过程中的关键高级领导职位。Jim 的丰富经验将为 Mesoblast 提供所需的财务领导，以便在商业化 Ryoncil®并期待标签扩展时发挥作用。他的技能将与我们的财务负责人 Andrew Chaponnel 的技能相辅相成，实施与收入预测、融资和资本分配相关的稳健财务控制、报告和治理。”</p>
</div><p>Jim has had global responsibility overseeing Corporate and Business Unit finance, Reporting, Internal Controls and Accounting Operations at Actavis plc which subsequently acquired Allergan plc prior to its acquisition by AbbVie Inc. Jim created a world-class financial budgeting and forecasting process to track business performance and trends, and developed financial tools and analyses supporting a range of corporate activities including Business Strategy and Corporate Development, integrating international business acquisitions and managing activities for transactions of nearly $10 billion. During his tenure, Actavis had proforma revenues of over $8 billion. Previously, Jim built a finance team overseeing all supply chain and revenue management for Nycomed, a private equity owned company with $750 million revenues that was acquired by Sandoz for $1.5 billion. Jim’s recent CFO roles included NASDAQ-listed biopharmaceutical company Cognition Therapeutics, Inc., overseeing the company’s successful initial public offering, and at dual-listed Finnish biotechnology company Faron Pharmaceuticals, Ltd. He has also held finance roles at Bristol-Myers Squibb (BMS). Jim is a certified public accountant and previously worked at PriceWaterhouseCoopers in New York and Washington DC.</p>
<div class="lb-trans"><p>Jim 在 Actavis plc 担任全球责任，监督公司和业务单位的财务、报告、内部控制和会计运营，该公司随后收购了 Allergan plc，之后又被 AbbVie Inc.收购。Jim 创建了一个世界级的财务预算和预测流程，以跟踪业务绩效和趋势，并开发了支持一系列公司活动的财务工具和分析，包括商业战略和公司发展，整合国际业务收购并管理近 100 亿美元交易的活动。在他的任期内，Actavis 的预估收入超过 80 亿美元。此前，Jim 在 Nycomed 建立了一个财务团队，负责监督所有供应链和收入管理，该公司是一家私募股权拥有的公司，年收入为 7.5 亿美元，后来以 15 亿美元被 Sandoz 收购。Jim 最近的 CFO 角色包括纳斯达克上市的生物制药公司 Cognition Therapeutics, Inc.，监督公司的成功首次公开募股，以及在双重上市的芬兰生物技术公司 Faron Pharmaceuticals, Ltd.的工作。他还曾在百时美施贵宝（Bristol-Myers Squibb，BMS）担任财务职务。Jim 是一名注册会计师，曾在纽约和华盛顿特区的普华永道工作。</p>
</div><p><strong>About Mesoblast</strong></p>
<div class="lb-trans"><p><strong>关于 Mesoblast</strong></p>
</div><p>Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.</p>
<div class="lb-trans"><p>Mesoblast（公司）是开发用于治疗严重和危及生命的炎症疾病的同种异体（现成）细胞药物的全球领导者。该公司的专有间充质谱系细胞治疗技术平台的疗法通过释放抗炎因子来应对严重炎症，这些因子对免疫系统的多个效应臂进行反制和调节，从而显著减少有害的炎症过程。</p>
</div><p>Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.</p>
<div class="lb-trans"><p>Mesoblast 的 Ryoncil®（remestemcel-L-rknd）用于治疗 2 个月及以上儿童患者的类固醇难治性急性移植物抗宿主病（SR-aGvHD），是首个获得 FDA 批准的间充质基质细胞（MSC）疗法。请参见 www.ryoncil.com 上的完整处方信息。</p>
</div><p>Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.</p>
<div class="lb-trans"><p>Mesoblast 致力于基于其 remestemcel-L 和 rexlemestrocel-L 同种异体基质细胞技术平台开发针对不同适应症的额外细胞疗法。Ryoncil®正在开发用于包括成人 SR-aGvHD 和生物制剂耐药性炎症性肠病在内的其他炎症疾病。Rexlemestrocel-L 正在开发用于心力衰竭和慢性下背痛。该公司已在日本、欧洲和中国建立了商业合作伙伴关系。</p>
</div><p><strong>About Mesoblast intellectual property:</strong> Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.</p>
<div class="lb-trans"><p><strong>关于 Mesoblast 的知识产权：</strong> Mesoblast 拥有强大而广泛的全球知识产权组合，拥有超过 1000 项已授予的专利或专利申请，涵盖间充质基质细胞的物质组成、制造方法和适应症。这些已授予的专利和专利申请提供了商业保护，延续至至少 2044 年，涵盖所有主要市场。</p>
</div><p><strong>About Mesoblast manufacturing:</strong> The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.</p>
<div class="lb-trans"><p><strong>关于 Mesoblast 的制造：</strong> 该公司的专有制造工艺可生产工业规模的、冷冻保存的、现成的细胞药物。这些细胞疗法具有明确的药品释放标准，计划在全球范围内为患者提供。</p>
</div><p>Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast</p>
<div class="lb-trans"><p>Mesoblast 在澳大利亚、美国和新加坡设有办事处，并在澳大利亚证券交易所（MSB）和纳斯达克（MESO）上市。有关更多信息，请访问 www.mesoblast.com，LinkedIn: Mesoblast Limited 和 Twitter: @Mesoblast</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.</p>
<div class="lb-trans"><p>本新闻稿包含与未来事件或我们未来财务表现相关的前瞻性声明，并涉及已知和未知的风险、不确定性及其他因素，这些因素可能导致我们的实际结果、活动水平、表现或成就与这些前瞻性声明所表达或暗示的任何未来结果、活动水平、表现或成就存在重大差异。我们根据 1995 年《私人证券诉讼改革法案》和其他联邦证券法的安全港条款作出此类前瞻性声明。前瞻性声明不应被视为对未来表现或结果的保证，实际结果可能与这些前瞻性声明中预期的结果不同，而这些差异可能是重大且不利的。前瞻性声明包括但不限于关于：Mesoblast 的临床前和临床研究的启动、时间、进展和结果，以及 Mesoblast 的研发项目；Mesoblast 将产品候选者推进、招募并成功完成临床研究（包括多国临床试验）的能力；Mesoblast 提升其制造能力的能力；监管申请和批准、制造活动和产品营销活动的时间或可能性（如有）；Mesoblast 的 RYONCIL 用于儿童 SR-aGVHD 的商业化及任何其他产品候选者（如获批准）；围绕干细胞治疗的监管或公众认知及市场接受度；Mesoblast 的产品候选者（如有获批准）因患者不良事件或死亡而可能被撤回市场的潜在性；战略合作协议的潜在利益及 Mesoblast 进入和维持已建立的战略合作的能力；Mesoblast 在其产品候选者上建立和维持知识产权的能力，以及在涉嫌侵权案件中成功捍卫这些权利的能力；Mesoblast 能够为其产品候选者和技术建立和维持的知识产权保护范围；Mesoblast 的费用、未来收入、资本需求及其对额外融资的需求的估计；Mesoblast 的财务表现；与 Mesoblast 的竞争对手和行业相关的发展；以及 Mesoblast 的产品候选者（如获批准）的定价和报销。您应将本新闻稿与我们最近提交给 SEC 的报告或我们网站上的风险因素一起阅读。可能导致 Mesoblast 的实际结果、表现或成就与此类声明所表达或暗示的结果存在重大差异的不确定性和风险，因此，您不应对这些前瞻性声明过度依赖。我们不承担任何公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来发展还是其他原因。</p>
</div><p>Release authorized by the Chief Executive.</p>
<div class="lb-trans"><p>发布经首席执行官授权。</p>
</div><p><em>For more information, please contact:</em></p>
<div class="lb-trans"><p><em>如需更多信息，请联系：</em></p>
</div><p><em><strong>Corporate Communications / Investors</strong></em></p>
<div class="lb-trans"><p><em><strong>企业传播 / 投资者</strong></em></p>
</div><p>Paul Hughes</p>
<div class="lb-trans"><p>保罗·休斯</p>
</div><p>T: +61 3 9639 6036</p>
<div class="lb-trans"><p>电话：+61 3 9639 6036</p>
</div><p><em><strong>Media</strong></em> <em><strong>– Global</strong></em></p>
<div class="lb-trans"><p><em><strong>媒体</strong></em> <em><strong>– 全球</strong></em></p>
</div><p>Allison Worldwide</p>
<div class="lb-trans"><p>艾莉森全球</p>
</div><p>Emma Neal</p>
<div class="lb-trans"><p>艾玛·尼尔</p>
</div><p>T: +1 603 545 4843</p>
<div class="lb-trans"><p>电话：+1 603 545 4843</p>
</div><p>E: emma.neal@allisonworldwide.com</p>
<div class="lb-trans"><p>电子邮件：emma.neal@allisonworldwide.com</p>
</div><p><em><strong>Media – Australia</strong></em></p>
<div class="lb-trans"><p><em><strong>媒体 – 澳大利亚</strong></em></p>
</div><p>BlueDot Media</p>
<div class="lb-trans"><p>蓝点媒体</p>
</div><p>Steve Dabkowski</p>
<div class="lb-trans"><p>史蒂夫·达布科夫斯基</p>
</div><p>T: +61 419 880 486</p>
<div class="lb-trans"><p>电话：+61 419 880 486</p>
</div><p>E: steve@bluedot.net.au</p>
<div class="lb-trans"><p>电子邮件：steve@bluedot.net.au</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVM05qZzFOQ00zTWpZMk9UVXpJekl3TVRjME16ST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU3Njg1NCM3MjY2OTUzIzIwMTc0MzI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmEyNTdkZTEtYjA1OS00NGRhLWFjZDQtMjI1ZmVkYjU4YTQwLTEwMjkwMDUtMjAyNS0xMS0xNy1lbg==/tiny/Mesoblast-Limited.png" alt="" original-src="https://ml.globenewswire.com/media/ZmEyNTdkZTEtYjA1OS00NGRhLWFjZDQtMjI1ZmVkYjU4YTQwLTEwMjkwMDUtMjAyNS0xMS0xNy1lbg==/tiny/Mesoblast-Limited.png"/></p>

James M. O'Brien 被任命为 Mesoblast 的首席财务官 | MESO 股票新闻